FDA Approves First-in-Class Drug Bulevirtide for Chronic Hepatitis D
The U.S. Food and Drug Administration (FDA) has approved bulevirtide (Hepcludex®) for the treatment of adults with chronic hepatitis D virus (HDV) infection. This is the first drug approved in the U.S. for this severe disease, which rapidly leads to liver cirrhosis.
BULEVIRTIDE: The First Swallow, Followed by a Tsunami
[The Gist]: What's Really Happening
On May 21, 2026, the FDA officially approved Hepcludex (bulevirtide-gmod) for the treatment of chronic hepatitis D infection in adults—without cirrhosis or with compensated cirrhosis.
This is not just "another approval." It is the first and only drug on the U.S. market for a disease that, until today, officially had no approved therapy in the U.S.
For decades, patients with hepatitis D heard the same thing from doctors: "We have no treatment for you. We'll monitor you." The only option was pegylated interferon alfa—a drug with terrible toxicity, low efficacy, and no official FDA approval for this indication.
Bulevirtide changes the game. It is the first representative of an entirely new class of antivirals—entry inhibitors. Instead of attacking the virus from inside the cell, it blocks the entry gate: the NTCP protein on the surface of hepatocytes, which the virus uses as a receptor for entry.
The mechanism is elegantly brilliant. Bulevirtide is a synthetic lipopeptide that mimics the PreS1 fragment of the large HBV envelope protein. It binds to NTCP with high affinity and literally "plugs" the transport tunnel through which the virus enters the cell.
And yes, the side effect is predictable and even confirms the mechanism of action: increased bile acid levels in the blood. Because NTCP is a bile acid transporter. By blocking the virus, you also block its natural function.
Timeline and Context
2012: The Urban group (Heidelberg) discovers that NTCP is the functional receptor for HBV and HDV. This discovery provides the theoretical basis for developing entry inhibitors.
2020: The European Medicines Agency (EMA) approves bulevirtide at a dose of 2 mg/day. Europe beats the U.S. by 6 years.
November 2021: Gilead submits an application to the FDA based on interim data from the MYR301 study.
October 2022: The FDA issues a complete response letter. The reason? Not efficacy—that was fine. Problems with manufacturing and drug delivery.
Why this matters: The FDA did not reject bulevirtide itself. It rejected the application. The difference is huge. Gilead spent nearly 4 years bringing manufacturing processes into compliance.
May 2025: Gilead publishes final results from MYR301. Key finding: the longer a patient receives therapy, the higher the likelihood of a sustained virologic response after drug discontinuation.
May 21, 2026: The FDA finally approves Hepcludex. The dose is not 2 mg, as in Europe, but 8.5 mg once daily subcutaneously.
Numbers from the MYR301 study (n=open-label study, immediate treatment group vs. deferred):
- Combined response (undetectable HDV RNA or ≥2 log10 decline + ALT normalization) at week 48: 48% in the bulevirtide group vs. 2% in the deferred treatment group.
- Undetectable HDV RNA at week 48: 20% vs. 0%.
- By week 96: 36%.
- By week 144: 50%.
Note: The response deepens over time. This is not a quick effect. It is therapy designed for years.
Who Wins and Who Loses
Winners (obvious):
- Patients with HDV. Consider the scale of the tragedy: HDV is the most severe form of viral hepatitis. It leads to cirrhosis, hepatocellular carcinoma, and death faster than HBV monoinfection. In the U.S., HDV prevalence among HBV carriers is estimated at 2-4%. With 1.2-2.4 million chronic HBV carriers in the U.S., that's 24,000-96,000 patients who, until yesterday, had no approved therapy.
- Gilead Sciences. Formally, yes. But there is a subtle nuance (see next section).
- MYR GmbH. The German company that developed bulevirtide (originally called Myrcludex B). Gilead acquired MYR GmbH back in 2020. The deal amount was not disclosed, but Gilead's reports include a contingent consideration of $275 million USD, tied to bulevirtide approval timelines. This approval just zeroed out or confirmed that payment.
Losers:
- Eiger BioPharmaceuticals (developer of lonafarnib). Lonafarnib is a prenylation inhibitor that completed Phase III but showed limited efficacy after drug discontinuation. Without a sustained off-therapy response, lonafarnib loses to bulevirtide.
- Pegylated interferon lambda. The study was terminated due to hepatotoxicity. Another competitor is out.
- Healthcare systems in the short term. 8.5 mg subcutaneously daily is expensive. The exact price of Hepcludex in the U.S. has not been announced, but in Europe, the course costs tens of thousands of euros per year. Insurers will push back.
What the Media Isn't Saying
Non-obvious Insight #1: Gilead Didn't Really Want This Drug
Yes, it sounds counterintuitive. But look at the numbers.
In recent months, Gilead spent $12 billion USD in upfront payments alone on three major deals: Arcellx (up to $7.8 billion USD), Tubulis ($5 billion USD, closed May 21, 2026—the same day the FDA approved Hepcludex), and Ouro Medicines (over $2 billion USD).
Twelve billion on oncology and immunology.
And bulevirtide? A contingent consideration of $275 million USD tied to approval timelines. For a company with a market cap near $100 billion USD, that's pocket change.
What does this mean? Gilead does not see HDV as a strategic priority. Yes, they brought the drug to approval because they had a contractual obligation to MYR GmbH. But all resources—money, management attention, R&D capacity—are thrown at ADCs (antibody-drug conjugates) and cell therapy.
For HDV patients, this is bad news. Gilead will not aggressively promote Hepcludex. It will not invest billions in expanding indications. The drug will remain niche.
Non-obvious Insight #2: The Boxed Warning Is Not Just a Formality
The drug labeling includes the most serious FDA warning—a boxed warning: discontinuation of bulevirtide may cause severe exacerbation of HDV and HBV infection.
Translating from regulatory to human: You cannot just stop taking this drug. If you start, be prepared for years of therapy. And if you decide to stop, you risk hospitalization with acute liver failure.
This radically changes the risk/benefit profile. For a patient with early fibrosis and asymptomatic HDV, the question "should I start therapy" becomes a complex moral-ethical decision.
Non-obvious Insight #3: 8.5 mg Is an Excessive Dose
In Europe, the approved dose is 2 mg. In the U.S., it's 8.5 mg. Why?
Answer: The FDA required a more conservative approach. In the MYR301 study, patients received either 2 mg or 10 mg. There was no difference in efficacy between doses, but the safety profile at 10 mg was slightly worse (more local reactions, more bile acid elevation). The FDA chose a dose in between—8.5 mg—likely due to manufacturing or stability issues.
For the patient, this means: you are getting a dose 4 times higher than the European one without proven additional benefit. Side effects will be more frequent. The price will be higher.
Forecast: Next 30 Days and 90 Days
30 days (by end of June 2026):
- Price war. Gilead will announce the U.S. price of Hepcludex. My forecast: between $150,000 and $250,000 USD per year (based on daily injections). Insurers (especially Medicare) will try to limit coverage to only the most severe cases—cirrhosis or rapid fibrosis progression.
- AASLD guideline update (American Association for the Study of Liver Diseases). Bulevirtide will be included as first-line therapy. Interferon alfa will go down in history.
- First prescriptions. Approximately 500-1,000 of the most informed patients in the U.S. will receive prescriptions within the first month. The rest will wait for their hepatologists to figure out logistics (the drug requires daily injections—it's not a pill).
90 days (by end of August 2026):
- Compliance issues. Daily subcutaneous injections are tough for patients. Expect a real-world discontinuation rate of about 15-20% in the first three months, despite the boxed warning.
- New clinical trials. Gilead will start (or has already started) a study on combining bulevirtide with other agents. The most interesting combination is with siRNA drugs targeting HBsAg (e.g., JNJ-3989 or Gilead's own GS-2829). This is the path to functional cure.
- FDA post-marketing requirements. Since Hepcludex was approved via the accelerated approval pathway, the FDA will require confirmatory studies for conversion to full approval. These studies are already underway, but final results will be in 2-3 years.
And the main forecast: By the end of 2026, it will become clear that bulevirtide is not the final point in HDV treatment. It is the first chapter. The real revolution will come with combination regimens that allow not just suppression of HDV RNA, but achieving HBsAg loss—that is, functional cure of HBV, without which HDV could theoretically return.
For now—applause for HDV patients. They have waited for this approval for over 40 years. Now it's here. Even if it comes in the form of daily injections, costing as much as a new car each year, with the risk of flare upon discontinuation.
But it exists. The first one. And that is already a victory.
— Editorial Team
